Kezar Life Sciences’ (KZR) “Market Perform” Rating Reaffirmed at William Blair

Kezar Life Sciences (NASDAQ:KZR)‘s stock had its “market perform” rating reiterated by analysts at William Blair in a research note issued on Wednesday,RTT News reports.

Separately, HC Wainwright reiterated a “neutral” rating on shares of Kezar Life Sciences in a research note on Monday, October 14th.

Kezar Life Sciences Trading Up 0.7 %

Shares of Kezar Life Sciences stock opened at $7.49 on Wednesday. The firm has a market capitalization of $54.68 million, a price-to-earnings ratio of -0.55 and a beta of 0.22. Kezar Life Sciences has a 12-month low of $5.20 and a 12-month high of $11.35. The firm’s 50 day simple moving average is $7.09 and its two-hundred day simple moving average is $6.84. The company has a current ratio of 9.58, a quick ratio of 9.58 and a debt-to-equity ratio of 0.05.

Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($2.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.20) by $0.40. Analysts predict that Kezar Life Sciences will post -11.95 EPS for the current year.

Institutional Trading of Kezar Life Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mackenzie Financial Corp purchased a new position in Kezar Life Sciences during the second quarter valued at $35,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Kezar Life Sciences during the second quarter valued at $63,000. BNP Paribas Financial Markets lifted its holdings in Kezar Life Sciences by 35.4% during the first quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock valued at $247,000 after purchasing an additional 71,543 shares in the last quarter. Acuitas Investments LLC lifted its holdings in Kezar Life Sciences by 42.8% during the second quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock valued at $592,000 after purchasing an additional 295,956 shares in the last quarter. Finally, Stonepine Capital Management LLC purchased a new position in Kezar Life Sciences during the second quarter valued at $630,000. Institutional investors and hedge funds own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.